Zevenbergen Capital Investments LLC Has $77.32 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Zevenbergen Capital Investments LLC lowered its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 4.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,376,057 shares of the medical research company’s stock after selling 57,518 shares during the quarter. Exact Sciences accounts for about 1.6% of Zevenbergen Capital Investments LLC’s holdings, making the stock its 21st largest position. Zevenbergen Capital Investments LLC’s holdings in Exact Sciences were worth $77,321,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. RPg Family Wealth Advisory LLC acquired a new stake in shares of Exact Sciences during the third quarter valued at approximately $34,000. Asset Planning Inc bought a new stake in Exact Sciences in the fourth quarter worth approximately $40,000. Modus Advisors LLC bought a new stake in Exact Sciences in the fourth quarter worth approximately $43,000. AlphaQuest LLC grew its position in Exact Sciences by 22,825.0% in the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock worth $52,000 after acquiring an additional 913 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in Exact Sciences in the fourth quarter worth approximately $66,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Price Performance

EXAS opened at $45.62 on Monday. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The company has a market cap of $8.47 billion, a price-to-earnings ratio of -8.19 and a beta of 1.25. The stock has a fifty day simple moving average of $50.55 and a two-hundred day simple moving average of $58.28. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.23. The firm had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. Research analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on EXAS. Scotiabank upped their price objective on shares of Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Monday, February 24th. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 20th. BTIG Research upped their price objective on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Barclays decreased their price objective on shares of Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Finally, Benchmark reaffirmed a “buy” rating and set a $65.00 price objective on shares of Exact Sciences in a report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $70.83.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.